Status:
TERMINATED
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
Lead Sponsor:
Centre Jean Perrin
Conditions:
Metastatic Breast Cancer
Colorectal Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The purpose of this study is to evaluate the efficacy of the implementation of an educational program on adherence to capecitabine alone or in combination to lapatinib.
Detailed Description
200 subjects who meet the inclusion/exclusion criteria treated by capecitabine +/- lapatinib, will be enrolled into the study. Adherence to treatment of all subjects will be assessed during a first ad...
Eligibility Criteria
Inclusion
- Age\> 18 years
- histologically confirmed breast cancer or colorectal cancer
- Patient starting oral treatment : capecitabine alone or in combination with lapatinib (can be included before the first cycle or during the first 2 cycles).
- Volunteer to participate in the study.
- ambulatory treated patient
- Able to read, write and understand French.
- Subject who accept to use MEMS monitors to automatically compile their drug dosing histories
- Written informed consent
Exclusion
- more than 3 metastatic chemotherapies
- any severe concomitant condition which makes it undesirable for the patient to participate in the study or which would jeopardize adherence with trial protocol
Key Trial Info
Start Date :
September 6 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 2 2017
Estimated Enrollment :
65 Patients enrolled
Trial Details
Trial ID
NCT01847599
Start Date
September 6 2011
End Date
July 2 2017
Last Update
July 21 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Jean Perrin
Clermont-Ferrand, France, 63011